Latest Equity Capital News

Cash Converters International Limited has announced the recommencement of its Dividend Reinvestment Plan (DRP) effective 20 February 2026, restoring shareholders’ ability to reinvest dividends into additional shares with favourable terms.

Advanced Innergy Holdings Ltd (ASX:AIH) has reported a robust FY25 performance highlighted by a successful IPO and strong growth across its core segments, setting a confident tone for FY26.

Bell Financial Group delivered a robust 17.1% rise in net profit after tax to $36 million for 2025, driven by strong growth in its Platforms division and a rebound in market activity. The company declared a fully franked final dividend of 6.5 cents per share, signalling confidence as it prepares to launch a new wealth management platform in 2026.

Oneview Healthcare PLC reported a 21% increase in total revenue to €12 million for the year ended 31 December 2025, driven by growth in recurring revenue and customer expansion. Despite this, the company’s loss after tax widened to €12.6 million, reflecting ongoing investment and cost pressures.

PYC Therapeutics has initiated a substantial capital raising effort, aiming to secure up to A$653 million to propel its four RNA therapeutic candidates through critical clinical milestones. The retail entitlement offer opens today, following a successful institutional placement.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Nova Minerals plans to redomicile to the United States following the loss of its foreign private issuer status, while acquiring full ownership of its Estelle Gold and Critical Minerals Project and appointing a US-based CFO.

Resolution Minerals has taken a significant step towards expanding its footprint in the US capital markets by lodging a registration statement with the SEC and launching an ADR facility, while divesting a non-core Alaskan asset to focus on key US projects.

PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.

Enova Mining has reported significant near-surface titanium, rare earth, and niobium mineralisation at its CODA projects in Brazil, alongside ongoing diamond drilling at East Salinas targeting high-grade rare earth zones.

Kalamazoo Resources reported a $340,000 cash outflow for the December quarter, with cash reserves dwindling to $284,000. The company has since raised $8 million through a January placement and is pursuing further funds via a share purchase plan.

Vulcan Energy Resources reported a strong financing quarter with €509 million raised, offsetting operating and investing cash outflows and leaving the company well-funded heading into 2026.